A major challenge to treating glioblastoma is its highly invasive nature, as infiltrating cancer cells are “protected” from exposure to systemically administered therapies by the blood brain barrier (BBB). To overcome this physical barrier, we non-invasively open the BBB via the activation of intravascular microbubbles (MBs) with MRI-guided focused ultrasound (FUS). In this proposal, we will deliver anti-CD47 immunotherapy (mCD47) to gliomas. CD47, a surface molecule expressed by cancer cells that sends a so-called “don’t eat me” signal to phagocytic cells, has garnered considerable attention recently because functionally blocking CD47 elicits control of many neoplasms, including primary brain tumors. We will determine, through the use of 89 Zr- ImmunoPET imaging, how the timing and sequencing of FUS application with respect to drug administration affects mCD47 delivery.
No reports found.